# Tom Cahill

> Thomas J. Cahill, MD, PhD is the founder and managing partner of Newpath Partners, a Boston-based life sciences venture firm he built from the ground up to translate breakthrough academic science into medicines. A structural biologist trained under two Nobel laureates, Cahill has co-founded more than a dozen biotech companies — including Prime Medicine, Chroma Medicine, and Autobahn Therapeutics — and became one of the pandemic's most consequential behind-the-scenes operators when he assembled Scientists to Stop COVID-19, a coalition that fed curated research directly to the White House and helped redirect Regeneron's manufacturing to Dublin.

- **Role:** Founder and Managing Partner at Newpath Partners
- **Organizations:** Newpath Partners, Scientists to Stop COVID-19, Prime Medicine, Chroma Medicine / nChroma Bio, Exo Therapeutics, Kisbee Therapeutics, Autobahn Therapeutics, Kojin Therapeutics, Magnet Biomedicine, Myeloid Therapeutics, Nvelop Therapeutics, YourBio Health, Leal Therapeutics, Metsera, Molindra Therapeutics, Arena BioWorks, Mammoth Biosciences, Raptor Group
- **Nationality:** American (Irish-American heritage)
- **Education:** B.S. in Chemistry, Hobart and William Smith Colleges, Undergraduate Research (Nobel Laureate Roald Hoffmann lab, theoretical chemistry), Cornell University, M.S. in Chemistry (reaction dynamics research under Prof. Richard Zare), Stanford University, M.D. and Ph.D. (structural biology; rare genetic diseases; Nobel Laureate Robert Lefkowitz lab), Duke University
- **Known for:** Founded Newpath Partners from scratch, growing it to two funds totaling ~$475M, Co-founded 15+ biotech companies including Prime Medicine (NYSE: PRME), a publicly traded gene editing company, Led Scientists to Stop COVID-19, which influenced federal policy on vaccine manufacturing and deployment

## Career timeline

- **2005-2009** — Studied chemistry at Hobart and William Smith Colleges; conducted undergraduate research with Nobel Laureate Roald Hoffmann at Cornell
- **2009-2011** — M.S. in Chemistry at Stanford University, researching reaction dynamics under Professor Richard Zare
- **2011-2018** — M.D. and Ph.D. at Duke University; completed doctoral research on cellular receptors and signaling under Nobel Laureate Robert Lefkowitz; published peer-reviewed work on rare genetic diseases
- **2018** — Joined Raptor Group to manage life science, healthcare, and technology investment portfolio
- **2018** — Founded Newpath Partners in Boston with approximately $125 million in initial capital; began co-founding companies with top academic scientists
- **2020** — Assembled Scientists to Stop COVID-19 in March 2020 — a non-partisan coalition of leading researchers and billionaires that fed curated research to policymakers; helped expedite FDA approval for Regeneron to shift manufacturing to Dublin
- **2021** — Launched Newpath Partners Fund II at $350 million, partnering with David Liu, Ben Cravatt, Keith Joung, Stuart Schreiber, and Ron Vale
- **2022** — Prime Medicine (PRME) launched with $315 million financing, with Cahill as a board director
- **2024** — Co-founded Arena BioWorks in Cambridge alongside Stuart Schreiber and Steve Pagliuca, backed by $500 million
- **2024** — Newpath portfolio companies raise cumulative total exceeding $4 billion

## Achievements

- Founded Newpath Partners from scratch, growing it to two funds totaling ~$475M
- Co-founded 15+ biotech companies including Prime Medicine (NYSE: PRME), a publicly traded gene editing company
- Led Scientists to Stop COVID-19, which influenced federal policy on vaccine manufacturing and deployment
- Helped redirect Regeneron Pharmaceuticals' manufacturing to Dublin during the COVID-19 pandemic through direct government access
- Trained under two Nobel Laureates in chemistry and biology (Roald Hoffmann, Robert Lefkowitz) and worked under a third (Michael Rosbash praised his COVID work)
- Portfolio companies have raised more than $4 billion in total financing
- Founded Molindra Therapeutics targeting a novel receptor class identified through his doctoral research
- Co-founded Arena BioWorks with $500M backing (one of the largest biomedical institute launches of 2024)

## Latest updates

- **2024-12** — Newpath Partners co-invested in nChroma Bio Series A, focused on chromatin biology and gene regulation
- **2024-11** — Arena BioWorks, which Cahill co-founded in early 2024, shut down due to biotech funding environment pressures
- **2024-11** — Portfolio company Metsera raised $215M Series B for weight loss treatments with Newpath participation
- **2024-01** — Co-founded Arena BioWorks in Cambridge with Stuart Schreiber, Steve Pagliuca, and $500M in backing

## Links

- Website: https://www.newpath.partners/
- LinkedIn: https://www.linkedin.com/in/tom-cahill-861a245
- Twitter/X: https://twitter.com/tomcahill89

---

Profile page: https://yespress.io/tom-cahill
Published by YesPress — https://yespress.io
Last updated: 2026-05-06